J&J's im­pend­ing split; And the next FDA com­mish is...; Aduhelm back in spot­light; #AHA21; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

As we mark the 40th edi­tion of this Sat­ur­day re­cap, I’d like to spend a mo­ment mar­veling at just how much End­points News has grown in the past year. We used to just have two dai­ly re­ports. But we now send out week­ly email newslet­ters ded­i­cat­ed to phar­ma mar­ket­ing (End­points Mar­ket­ingRx), reg­u­la­to­ry news (End­points FDA+) and man­u­fac­tur­ing (End­points Man­u­fac­tur­ing). Want to get them in your in­box? You can cus­tomize your list of sub­scrip­tions in the read­er pro­file.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER